angiogenesis inhibitors

Preferred Label : angiogenesis inhibitors;

MeSH definition : Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.;

MeSH synonym : anti-angiogenetic agents; inhibitors, angiogenetic; inhibitors, angiogenic; antagonists, angiogenic; inhibitors, neovascularization; antagonists, angiogenetic; angiogenetic antagonists; anti angiogenetic agents; agents, anti-angiogenetic; anti-angiogenic drugs; angiogenic antagonists; inhibitors, angiogenesis; angiostatic agents; agents, angiostatic; anti angiogenic drugs; drugs, anti-angiogenic; neovascularization inhibitors; angiogenetic inhibitors; angiogenic inhibitors; antiangiogenic agents; agents, antiangiogenic; Angiogenesis Inhibitor; Inhibitor, Angiogenesis; Angiogenetic Antagonist; Antagonist, Angiogenetic; Angiogenetic Inhibitor; Inhibitor, Angiogenetic; Angiogenic Antagonist; Antagonist, Angiogenic; Angiogenic Inhibitor; Inhibitor, Angiogenic; Angiostatic Agent; Agent, Angiostatic; Anti-Angiogenetic Agent; Agent, Anti-Angiogenetic; Anti Angiogenetic Agent; Anti-Angiogenic Drug; Anti Angiogenic Drug; Drug, Anti-Angiogenic; Neovascularization Inhibitor; Inhibitor, Neovascularization; Antiangiogenic Agent; Agent, Antiangiogenic;

MeSH hyponym : angiogenesis factor inhibitors; Factor Inhibitors, Angiogenesis; Inhibitors, Angiogenesis Factor; Angiogenesis Factor Inhibitor; Factor Inhibitor, Angiogenesis; Inhibitor, Angiogenesis Factor;

Related MeSH term : Anti-Angiogenesis effect; Anti Angiogenesis Effect; Effect, Anti-Angiogenesis; Antiangiogenesis Effect; Effect, Antiangiogenesis; Antiangiogenesis Effects; Effects, Antiangiogenesis; Anti-Angiogenesis Effects; Anti Angiogenesis Effects; Effects, Anti-Angiogenesis;

MeSH annotation : note entry term ANTI-ANGIOGENESIS EFFECT: use only for the anti-angiogenesis effect of a chemical substance;

Wikipedia link : https://en.wikipedia.org/wiki/Angiogenesis inhibitor;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D020533;

UMLS CUI

C0596087;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Angiogenesis inhibitor (disposition) [SNOMED CT concept]
- Antiangiogenesis Therapy [NCIt concept]
Currated CISMeF NLP mapping
- Angiogenesis Inhibitor [NCIt concept]
- Product containing angiogenesis inhibitor (product) [SNOMED CT concept]
- Substance with angiogenesis inhibitor mechanism of action (substance) [SNOMED CT concept]
Indexing information
- 1-((3-chloromethyl)phenyl)-3-prop-2-ynylurea [MeSH Supplementary Concept]
- 1-(4-fluoro-3-methoxybenzyl)-N-(9-chloro-3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylpyrrolidine-3-carboxamide [MeSH Supplementary Concept]
- 2-(benzylsulfinyl)ethyl pyridin-3-ylmethylcarbamodithioate [MeSH Supplementary Concept]
- 3,4-dimethoxystilbene [MeSH Supplementary Concept]
- 3-azidowithaferin A [MeSH Supplementary Concept]
- CA-104 [MeSH Supplementary Concept]
- CIBP-4 peptide [MeSH Supplementary Concept]
- G0811 compound [MeSH Supplementary Concept]
- GNX-686 [MeSH Supplementary Concept]
- H-RN peptide [MeSH Supplementary Concept]
- HS-106 [MeSH Supplementary Concept]
- Jiedu Xiaozheng Yin [MeSH Supplementary Concept]
- LHT7 compound [MeSH Supplementary Concept]
- N-acetyl-5-ferrocenyl-3-(2-thienyl)-2-pyrazoline [MeSH Supplementary Concept]
- N-methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide [MeSH Supplementary Concept]
- N1,N12-bis(retinoyl)spermine [MeSH Supplementary Concept]
- N6L peptide [MeSH Supplementary Concept]
- R1498 compound [MeSH Supplementary Concept]
- RGDechi-hCit peptide [MeSH Supplementary Concept]
- Resveratrol [MeSH Descriptor]
- SKLB1002 [MeSH Supplementary Concept]
- TR-644 [MeSH Supplementary Concept]
- anecortave acetate [MeSH Supplementary Concept]
- bastadin 16 [MeSH Supplementary Concept]
- cRGD-LHT7 [MeSH Supplementary Concept]
- kushecarpin D [MeSH Supplementary Concept]
- lebectin protein, macrovipera lebetina [MeSH Supplementary Concept]
- lodamin [MeSH Supplementary Concept]
- pazopanib [MeSH Supplementary Concept]
- sikkimenoid B [MeSH Supplementary Concept]
- wen luo yin [MeSH Supplementary Concept]
Record concept(s)
- Anti-Angiogenesis effect [MeSH concept]
- angiogenesis factor inhibitors [MeSH concept]
- angiogenesis inhibitors [MeSH concept]
See also (suggested by CISMeF)
- angiogenesis inducing agents [MeSH Descriptor]
- neovascularization, physiologic [MeSH Descriptor]
Semantic type(s)
- Biologically Active Substance [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 2-(benzylsulfinyl)ethyl pyridin-3-ylmethylcarbamodithioate [MeSH Supplementary Concept]
- 5-nitro-2-(3-phenylpropylamino)benzoic acid [MeSH Supplementary Concept]
- Angiopoietin-Like Protein 1 [MeSH Descriptor]
- Bevacizumab [MeSH Descriptor]
- CKD732 [MeSH Supplementary Concept]
- CNMD protein, human [MeSH Supplementary Concept]
- Interleukin-12 [MeSH Descriptor]
- Interleukin-23 [MeSH Descriptor]
- Lenalidomide [MeSH Descriptor]
- O-(Chloroacetylcarbamoyl)fumagillol [MeSH Descriptor]
- RC28-E protein [MeSH Supplementary Concept]
- Ranibizumab [MeSH Descriptor]
- Sunitinib [MeSH Descriptor]
- aflibercept [MeSH Supplementary Concept]
- anecortave [MeSH Supplementary Concept]
- angiostatic proteins [MeSH Descriptor]
- angiostatins [MeSH Descriptor]
- cytochalasin E [MeSH Supplementary Concept]
- endostar protein [MeSH Supplementary Concept]
- endostatins [MeSH Descriptor]
- faricimab [MeSH Supplementary Concept]
- fumagillin [MeSH Supplementary Concept]
- halofuginone [MeSH Supplementary Concept]
- pomalidomide [MeSH Supplementary Concept]
- roquinimex [MeSH Supplementary Concept]
- semaxinib [MeSH Supplementary Concept]
- small inducible cytokine subfamily E, member 1 [MeSH Supplementary Concept]
- squalamine [MeSH Supplementary Concept]
- tetra(4-N-methylpyridyl)porphine [MeSH Supplementary Concept]
- tetrathiomolybdate [MeSH Supplementary Concept]
- thalidomide [MeSH Descriptor]
- thymogen [MeSH Supplementary Concept]
- trebananib [MeSH Supplementary Concept]
- tumor necrosis factor ligand superfamily member 15 [MeSH Descriptor]
- volociximab [MeSH Supplementary Concept]
- xanthohumol [MeSH Supplementary Concept]
- zhengguangmycin [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Angiogenesis Inhibitor [NCIt concept]
- Product containing angiogenesis inhibitor (product) [SNOMED CT concept]
- Substance with angiogenesis inhibitor mechanism of action (substance) [SNOMED CT concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients